A select group of small cap stocks will join Proactive’s Steve Darling at the digital financial news organization’s upcoming virtual investor conference on at 1pm ET on Tuesday, August 4.
The virtual One2One Investor Forum event is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and some of North America’s most innovative businesses.
The three companies participating on Tuesday are medical device developer BioSig Technologies Inc (NASDAQ:BSGM), gene therapy company Genprex Inc (NASDAQ:GNPX) and agriculture technology company Clean Seed Capital Group (CVE:CSX).
Building a better ECG machine
BioSig Technologies, based in Westport, Connecticut, is commercializing a biomedical signal processing platform called PURE EP, which is designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals.
The company is also doing its part to combat the coronavirus, through its subsidiary ViralClear Pharmaceuticals Inc. ViralClear is currently enrolling patients for a Phase 2 trials of its drug merimepodib, an orally administered therapy that has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 (the virus that causes the COVID-19 disease) in cell cultures.
CEO and chairman Kenneth Londoner will present on behalf of the company.
READ: BioSig Technologies subsidiary ViralClear forms Scientific Advisory Board with two industry veterans experienced as both regulators and corporate executives
“With our stock up 34% year-to-date and the strongest balance sheet in the company’s history, we are well-positioned for continuous value creation on behalf of our shareholders,” Londoner said in a recent statement. “Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP System’s ongoing and future installations. Our pharmaceutical subsidiary ViralClear sees a steady patient enrollment across many hospital sites.”
Clean Seed’s SMART farming technologies
Clean Seed Capital Group is working full tilt at driving technology advancements in farming. The Canadian company has created the CX-6 SMART Seeder, a machine with the ability to plant six different crops, at three different depths with military precision.
The beauty of the CX-6 SMART Seeder for farmers and agriculture scientists is that the hulking high-output planter is wirelessly controlled through a tablet running on the company’s intuitive SeedSync software system.
Burnaby, British Columbia-based Clean Seed has not stopped with the CX-6 SMART seeder, having just rolled out a highly advanced, lighter version of its planter. The company teamed up with joint venture partner North Dakota-based Norwood to give farmers the new Smart Seeder Max and Smart Seeder Max S.
“This partnership optimizes our ability to deliver growth, rapidly and reliably with an invested partner. Our teams are also collaborating on several additional opportunities that will further differentiate our offerings,” CEO Graeme Lempriere said.
A lung cancer therapy and a possible cure for diabetes
Genprex is developing a robust pipeline of drugs, headlined by its non-small cell lung cancer (NSCLC) drug candidate GPX-001, formerly known as Oncoprex. The drug works by interrupting cell signaling pathways that cause the replication and proliferation of cancer cells.
The drug received Fast Track Designation from the US Food and Drug Administration (FDA) for use in combination with AstraZeneca’s drug Tagrisso in late-stage lung cancer patients with epidermal growth factor receptor (EGFR) mutations whose tumors progress on Tagrisso alone.
READ: Genprex boss Rodney Varner gives second live interview on nationally syndicated TV and radio show the ‘Big Biz Show’
The trial with Tagrisso is expected to be initiated in early 2021, and the company is also planning a clinical trial in combination with Keytruda, a cancer drug from Merck & Co Inc (NYSE:MRK).
The Austin-based company is also working on a preclinical diabetes gene therapy candidate, GPX-002, that it claims may have the potential to cure Type 1 and Type 2 diabetes.
CEO and Chairman Rodney Varner will present an update on the company’s pipeline, including both GPX-001 and GPX-002, beginning at 1:40 pm ET.
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel